BD and Biosero Join Forces for Robotic Integration in Drug Discovery

BD and Biosero Enhance Drug Discovery with Robotic Integration

A Powerful Collaboration for Scientific Advancement

In a significant move to revolutionize laboratory automation in drug discovery and development, BD (Becton, Dickinson and Company) has entered into a collaborative framework with Biosero, a well-known name in laboratory automation solutions. This partnership aims to facilitate the integration of robotic arms with BD's innovative flow cytometry instruments, streamlining crucial processes in drug development.

This collaboration focuses on enhancing the capabilities of BD's flow cytometry instruments by incorporating new software capabilities compatible with Biosero's renowned Green Button Go® software. The companies intend to jointly assist biopharmaceutical and contract research organizations by providing customized solutions that will enable smooth robotic arm integration.

Embracing Automation in Drug Development

Traditionally, the workflow associated with flow cytometry in drug discovery has required numerous manual interventions, which are not only time-consuming but also prone to human error. For instance, the process of loading and analyzing samples on a flow cytometer usually involves handling a multiwell plate, one at a time, thereby amounting to considerable downtime.

With the new robotic integration, however, it becomes feasible to handle multiple multiwell plates simultaneously, significantly reducing the need for manual input. Automation stands as a critical element, particularly for biopharma companies and contract research organizations that depend on the scalability and speed that robotic technology provides.

Steve Conly, the worldwide president of BD Biosciences, expressed his enthusiasm about the partnership, stating, "This collaboration unlocks a new chapter of automation for our current and future biopharma partners. By combining forces with Biosero, a trusted leader in lab automation, we will empower customers to bring their potentially life-changing therapies to market even faster."

The Role of Flow Cytometry in Drug Discovery

Flow cytometry serves as an indispensable instrument throughout various phases of drug discovery and development. It allows researchers to study the effects of drug candidates on individual cells within extensive populations. Additionally, in cell therapy manufacturing, flow cytometry facilitates the analysis and characterization of cells across different stages, ensuring that the final cell therapy product is both safe and effective.

Biosero’s suite of laboratory automation software is designed to function seamlessly with flow cytometers, robotic arms, and mobile robots, creating a unified ecosystem that automates complex scientific protocols. According to Ryan Bernhardt, CEO of Biosero, this collaboration promotes the vision of creating a laboratory environment that's not just efficient but also adaptable to the ever-evolving needs of drug development.

Looking Ahead: Integration and Innovation

The new versions of BD flow cytometer instrument software, which will be compatible with Biosero's automation technologies, are projected to be available for research use in 2025. This roll-out will include compatibility for the BD FACSymphony A1™ Cell Analyzer, the BD FACSymphony™ A5 SE Cell Analyzer, and the BD FACSLyric™ Flow Cytometry System. Furthermore, plans are underway for future integration with the BD FACSDiscover™ family of instruments.

This strategic collaboration between BD and Biosero not only signifies a leap forward in laboratory automation but also holds the promise of accelerating the pace of scientific discovery, ultimately leading to groundbreaking advancements in the field of medicine. For further information regarding BD and this collaboration, individuals can visit bd.com or explore Biosero’s solutions at biosero.com.